Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease?. Gastroenterol Clin North Am. 2005 Jun. 34(2):235-45, vi-vii. [QxMD MEDLINE Link].
Keefer L, Ballou SK, Drossman DA, Ringstrom G, Elsenbruch S, Ljotsson B. A Rome working team report on brain-gut behavior therapies for disorders of gut-brain interaction. Gastroenterology. 2022 Jan. 162(1):300-15. [QxMD MEDLINE Link]. [Full Text].
Chang L, Lembo A, Sultan S. Spotlight: IBS treatment. Gastroenterology. 2022 July. 163(1):153. [Full Text].
[Guideline] Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022 Jul. 163(1):137-51. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022 Jul. 163(1):118-36. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021 Jan 1. 116(1):17-44. [QxMD MEDLINE Link]. [Full Text].
Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017 Apr 30. 23(2):151-63. [QxMD MEDLINE Link]. [Full Text].
Drossman DA, Tack J. Rome Foundation clinical diagnostic criteria for disorders of gut-brain interaction. Gastroenterology. 2022 Mar. 162(3):675-9. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Brandt LJ, Chey WD, Foxx-Orenstein AE, et al, for the American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009 Jan. 104 suppl 1:S1-35. [QxMD MEDLINE Link]. [Full Text].
Singh P, Tuck C, Gibson PR, Chey WD. The role of food in the treatment of bowel disorders: focus on irritable bowel syndrome and functional constipation. Am J Gastroenterol. 2022 Jun 1. 117(6):947-57. [QxMD MEDLINE Link]. [Full Text].
National Center for Complementary and Integrative Health. September, 2016. Peppermint oil. Available at https://nccih.nih.gov/health/peppermintoil. Accessed: April 2, 2019.
Trulance (plecanatide) [package insert]. New York, NY: Synergy Pharmaceuticals Inc. January, 2018. Available at [Full Text].
Chey WD, Lembo AJ, Yan A, Rosenbaum DP. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3MPO-2) [abstract 885]. Presented at: Digestive Disease Week; June 2-5, 2018; Washington, DC. Gastroenterology. 2018 May. 54(6 suppl 1):S-1362. [Full Text].
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014. 6:71-80. [QxMD MEDLINE Link]. [Full Text].
Sperber AD, Dumitrascu D, f*ckudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017 Jun. 66(6):1075-82. [QxMD MEDLINE Link].
Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol. 2021 Jul 1. 116(7):1485-94. [QxMD MEDLINE Link]. [Full Text].
Zloof Y, Peretz L, Braun M, et al. Hypermobility spectrum disorders and irritable bowel syndrome: a nationwide study of 1.6 million adolescents. J Gastroenterol Hepatol. 2023 Dec. 38(12):2076-82. [QxMD MEDLINE Link]. [Full Text].
Bosman MHMA, Weerts ZZRM, Snijkers JTW, et al. The socioeconomic impact of irritable bowel syndrome: ananalysis of direct and indirect health care costs. Clin Gastroenterol Hepatol. 2023 Sep. 21(10):2660-9. [QxMD MEDLINE Link]. [Full Text].
Staller K, Olen O, Soderling J, et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. Am J Gastroenterol. 2020 May. 115(5):746-55. [QxMD MEDLINE Link]. [Full Text].
Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr. 2016 Dec. 3(1):11. [QxMD MEDLINE Link]. [Full Text].
Quigley EMM. The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS). J Clin Med. 2018 Jan 3. 7(1):6. [QxMD MEDLINE Link]. [Full Text].
Van den Houte K, Bercik P, Simren M, Tack J, Vanner S. Mechanisms underlying food-triggered symptoms in disorders of gut-brain interactions. Am J Gastroenterol. 2022 Jun 1. 117(6):937-46. [QxMD MEDLINE Link]. [Full Text].
Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May. 136(6):1979-88. [QxMD MEDLINE Link].
Tang HY, Jiang AJ, Wang XY, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021 Jul. 9(14):1187. [QxMD MEDLINE Link]. [Full Text].
Spiegel B. Gravity and the gut: a hypothesis of irritable bowel syndrome. Am J Gastroenterol. 2022 Dec 1. 117(12):1933-47. [QxMD MEDLINE Link]. [Full Text].
Chen M, Ruan G, Chen L, et al. Neurotransmitter and intestinal interactions: focus on the microbiota-gut-brain axis in irritable bowel syndrome. Front Endocrinol (Lausanne). 2022. 13:817100. [QxMD MEDLINE Link]. [Full Text].
Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec. 123(6):2108-31. [QxMD MEDLINE Link]. [Full Text].
DuPont AW, Jiang ZD, Harold SA, et al. Motility abnormalities in irritable bowel syndrome. Digestion. 2014. 89(2):119-23. [QxMD MEDLINE Link].
Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011 Jan. 23(1):8-23. [QxMD MEDLINE Link]. [Full Text].
Tornblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simren M. Colonic transit time and IBS symptoms: what's the link?. Am J Gastroenterol. 2012 May. 107(5):754-60. [QxMD MEDLINE Link].
Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016 Oct 30. 22(4):558-74. [QxMD MEDLINE Link]. [Full Text].
Camilleri M. Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms. J Physiol. 2014 Jul 15. 592(14):2967-80. [QxMD MEDLINE Link]. [Full Text].
[Guideline] f*ckudo S, Okumura T, Inamori M, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021 Mar. 56(3):193-217. [QxMD MEDLINE Link]. [Full Text].
Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018. 8:13. [QxMD MEDLINE Link]. [Full Text].
So D, Quigley EMM, Whelan K. Probiotics in irritable bowel syndrome and inflammatory bowel disease: review of mechanisms and effectiveness. Curr Opin Gastroenterol. 2023 Mar 1. 39(2):103-9. [QxMD MEDLINE Link]. [Full Text].
Kim GH, Lee K, Shim JO. Gut bacterial dysbiosis in irritable bowel syndrome: a case-control study and a cross-cohort analysis using publicly available data sets. Microbiol Spectr. 2023 Feb 14. 11(1):e0212522. [QxMD MEDLINE Link]. [Full Text].
Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 Dec. 123(6):1972-9. [QxMD MEDLINE Link].
Berumen A, Edwinson AL, Grover M. Post-infection irritable bowel syndrome. Gastroenterol Clin North Am. 2021 Jun. 50(2):445-61. [QxMD MEDLINE Link]. [Full Text].
Barbara G, Grover M, Bercik P, et al. Rome Foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019 Jan. 156(1):46-58.e7. [QxMD MEDLINE Link]. [Full Text].
Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020 Oct. 159(4):1526-32. [QxMD MEDLINE Link]. [Full Text].
Leite G, Rezaie A, Mathur R, et al, for the REIMAGINE Study Group. Defining small intestinal bacterial overgrowth by culture and high throughput sequencing. Clin Gastroenterol Hepatol. 2024 Feb. 22(2):259-70. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020 Feb. 115(2):165-78. [QxMD MEDLINE Link]. [Full Text].
Villanueva-Millan MJ, Leite G, Wang J, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022 Dec 1. 117(12):2055-66. [QxMD MEDLINE Link]. [Full Text].
Walters JRF. Making the diagnosis of bile acid diarrhea. Am J Gastroenterol. 2020 Dec. 115(12):1974-5. [QxMD MEDLINE Link].
Yu Z, Liu LY, Lai YY, et al. Altered resting brain functions in patients with irritable bowel syndrome: a systematic review. Front Hum Neurosci. 2022. 16:851586. [QxMD MEDLINE Link]. [Full Text].
Nistico V, Rossi RE, D'Arrigo AM, Priori A, Gambini O, Demartini B. Functional neuroimaging in irritable bowel syndrome: a systematic review highlights common brain alterations with functional movement disorders. J Neurogastroenterol Motil. 2022 Apr 30. 28(2):185-203. [QxMD MEDLINE Link]. [Full Text].
Chang L, Sundaresh S, Elliott J, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil. 2009 Feb. 21(2):149-59. [QxMD MEDLINE Link]. [Full Text].
Gros M, Gros B, Mesonero JE, Latorre E. Neurotransmitter dysfunction in irritable bowel syndrome: emerging approaches for management. J Clin Med. 2021 Jul 31. 10(15):3429. [QxMD MEDLINE Link]. [Full Text].
Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome - a review on the pathophysiology, current research and future therapy. Front Microbiol. 2019. 10:1136. [QxMD MEDLINE Link]. [Full Text].
Wensaas KA, Langeland N, Hanevik K, Morch K, Eide GE, Rortveit G. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 2012 Feb. 61(2):214-9. [QxMD MEDLINE Link].
Viswanathan L, Rao SS. Intestinal disaccharidase deficiency in adults: evaluation and treatment. Curr Gastroenterol Rep. 2023 Jun. 25(6):134-9. [QxMD MEDLINE Link]. [Full Text].
Henstrom M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut. 2018 Feb. 67(2):263-70. [QxMD MEDLINE Link]. [Full Text].
Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol. 2018 Oct. 16(10):1673-6. [QxMD MEDLINE Link]. [Full Text].
Ng QX, Yaow CYL, Moo JR, Koo SWK, Loo EXL, Siah KTH. A systematic review of the association between environmental risk factors and the development of irritable bowel syndrome. J Gastroenterol Hepatol. 2024 May 3. [QxMD MEDLINE Link]. [Full Text].
Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Frontline Gastroenterol. 2014 Oct. 5(4):266-71. [QxMD MEDLINE Link]. [Full Text].
Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. Aliment Pharmacol Ther. 2008 Oct 15. 28(8):1013-20. [QxMD MEDLINE Link]. [Full Text].
Khashan AS, Quigley EM, McNamee R, McCarthy FP, Shanahan F, Kenny LC. Increased risk of miscarriage and ectopic pregnancy among women with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012 Aug. 10(8):902-9. [QxMD MEDLINE Link].
Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015 Mar. 110(3):444-54. [QxMD MEDLINE Link].
Bohn L, Storsrud S, Tornblom H, Bengtsson U, Simren M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013 May. 108(5):634-41. [QxMD MEDLINE Link].
[Guideline] Hammer HF, Fox MR, Keller J, et al, for the European H2-CH4-breath test group. European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus. United European Gastroenterol J. 2022 Feb. 10(1):15-40. [QxMD MEDLINE Link]. [Full Text].
Rana SV, Malik A. Breath tests and irritable bowel syndrome. World J Gastroenterol. 2014 Jun 28. 20(24):7587-601. [QxMD MEDLINE Link]. [Full Text].
Shah A, Talley NJ, Jones M, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020 Feb. 115(2):190-201. [QxMD MEDLINE Link].
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003 Feb. 98(2):412-9. [QxMD MEDLINE Link].
Camilleri M. Irritable bowel syndrome: straightening the road from the Rome criteria. Neurogastroenterol Motil. 2020 Nov. 32(11):e13957. [QxMD MEDLINE Link]. [Full Text].
Tetali B, Suresh S. Management of irritable bowel syndrome: a narrative review. Transl Gastroenterol Hepatol. 2024. 9:26. [QxMD MEDLINE Link]. [Full Text].
Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan. 146(1):67-75.e5. [QxMD MEDLINE Link].
Nawawi KNM, Belov M, Goulding C. Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study. Eur J Nutr. 2020 Aug. 59(5):2237-48. [QxMD MEDLINE Link].
Valeur J, Smastuen MC, Knudsen T, Lied GA, Roseth AG. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. Dig Dis Sci. 2018 Feb. 63(2):429-36. [QxMD MEDLINE Link].
Khalighi Sikaroudi M, Soltani S, Ghoreishy SM, Ebrahimi Z, Shidfar F, Dehnad A. Effects of a low FODMAP diet on the symptom management of patients with irritable bowel syndrome: a systematic umbrella review with the meta-analysis of clinical trials. Food Funct. 2024 May 7. [QxMD MEDLINE Link].
Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar. 59(3):325-32. [QxMD MEDLINE Link].
Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014 May. 146(6):1554-63. [QxMD MEDLINE Link].
Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. J Infect. 2018 Feb. 76(2):111-20. [QxMD MEDLINE Link].
Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr. 104(4):1033-49; quiz 1050. [QxMD MEDLINE Link].
Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct. 109(10):1547-61; quiz 1546, 1562. [QxMD MEDLINE Link].
[Guideline] Su GL, Ko CW, Bercik P, et al. AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterology. 2020 Aug. 159(2):697-705. [QxMD MEDLINE Link]. [Full Text].
Knowles SR, Austin DW, Sivanesan S, et al. Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. Psychol Health Med. 2017 Jun. 22(5):524-34. [QxMD MEDLINE Link].
Hanna-Jairala I, Drossman DA. Central neuromodulators in irritable bowel syndrome: why, how, and when. Am J Gastroenterol. 2024 May 10. [QxMD MEDLINE Link]. [Full Text].
Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004 Dec. 2(12):1064-8. [QxMD MEDLINE Link].
[Guideline] Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021 Jul. 70(7):1214-40. [QxMD MEDLINE Link]. [Full Text].
US Food and Drug Administration. FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. August 30, 2012. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm. Accessed: May 12, 2015.
Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov. 107(11):1714-24; quiz p.1725. [QxMD MEDLINE Link]. [Full Text].
Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov. 107(11):1702-12. [QxMD MEDLINE Link].
Valeant Pharmaceuticals International, Inc. Salix announces FDA approval of Xifaxan 550 mg for the treatment of IBS-D (irritable bowel syndrome with diarrhea). Cision PR Newswire. May 27, 2015. Available at https://www.prnewswire.com/news-releases/salix-announces-fda-approval-of-xifaxan-550-mg-for-the-treatment-of-ibs-d-irritable-bowel-syndrome-with-diarrhea-300089821.html. Accessed: June 6, 2015.
Menees SB, Maneerattannap*rn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan. 107(1):28-35; quiz 36. [QxMD MEDLINE Link].
Pimentel M, Lembo A, Chey WD, et al, for the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6. 364(1):22-32. [QxMD MEDLINE Link]. [Full Text].
Zelnorm (tegaserod) [package insert]. Louisville, KY: Sloan Pharma. March 2019. Available at [Full Text].
Brooks M. FDA OKs reintroduction of tegaserod (Zelnorm) for IBS-C in women under 65. Medscape Medical News. April 2, 2019. Available at https://medscape.com/viewarticle/911237. Accessed: April 2, 2019.
Madia VN, Messore A, Saccoliti F, et al. Tegaserod for the treatment of irritable bowel syndrome. Antiinflamm Antiallergy Agents Med Chem. 2020. 19(4):342-69. [QxMD MEDLINE Link]. [Full Text].
Palsson OS, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [abstract Mo1642]. Gastroenterology. Apr 2016. 150(4 suppl 1):S739-40. [Full Text].
[Guideline] Ford AC, Moayyedi P, Chey WD, et al, for the ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018 Jun. 113(suppl 2):1-18. [QxMD MEDLINE Link]. [Full Text].
Rey E, Mearin F, Alcedo J, et al. Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report. Adv Ther. 2017 Mar. 34(3):587-98. [QxMD MEDLINE Link]. [Full Text].
Synergy Pharmaceuticals announces FDA approval of Trulance (plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults [press release]. Synergy Pharmaceuticals. January 25, 2018. Available at https://ir.synergypharma.com/press-releases/detail/1861/synergy-pharmaceuticals-announces-fda-approval-of. Accessed: January 25, 2018.
Lacy BE, Cangemi DJ. A pragmatic approach to the evaluation and treatment of abdominal bloating. Am J Gastroenterol. 2022 May 1. 117(5):701-5. [QxMD MEDLINE Link].
Quigley EMM. The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS). J Clin Med. 2018 Jan 3. 7(1):6. [QxMD MEDLINE Link]. [Full Text].
Peters S, Pascoe B, Wu Z, et al. Campylobacter jejuni genotypes are associated with post-infection irritable bowel syndrome in humans. Commun Biol. 2021 Aug 30. 4(1):1015. [QxMD MEDLINE Link]. [Full Text].
Noemi CN, Bob P, Bókkon I. Long-term implicit epigenetic stress information in the enteric nervous system and its ocntribution to developing and perpetuating IBS. Curr Neuropharmacol. 2024 May 9. [QxMD MEDLINE Link].
